Progyny (NASDAQ:PGNY) Price Target Raised to $25.00

Progyny (NASDAQ:PGNY) had its price objective increased by JPMorgan Chase & Co. from $23.00 to $25.00 in a research report report published on Tuesday morning,Benzinga reports. The brokerage currently has a neutral rating on the stock.

Several other research analysts also recently commented on PGNY. Leerink Partnrs raised shares of Progyny from a “hold” rating to a “strong-buy” rating in a research note on Tuesday, July 8th. Canaccord Genuity Group raised their price target on shares of Progyny from $21.00 to $23.00 and gave the stock a “hold” rating in a research note on Wednesday, August 20th. Raymond James Financial set a $28.00 price target on shares of Progyny in a research note on Friday, August 8th. Wall Street Zen raised shares of Progyny from a “hold” rating to a “buy” rating in a research note on Saturday, July 26th. Finally, Truist Financial raised their price target on shares of Progyny from $24.00 to $27.00 and gave the stock a “hold” rating in a research note on Thursday, July 17th. One research analyst has rated the stock with a Strong Buy rating, six have given a Buy rating and four have issued a Hold rating to the company. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and a consensus price target of $25.30.

Progyny Trading Up 1.0%

Shares of PGNY opened at $23.25 on Tuesday. Progyny has a twelve month low of $13.39 and a twelve month high of $26.76. The company has a market cap of $2.00 billion, a P/E ratio of 39.41, a P/E/G ratio of 1.88 and a beta of 1.32. The company’s fifty day simple moving average is $22.67 and its 200-day simple moving average is $22.19.

Progyny (NASDAQ:PGNY) last announced its earnings results on Thursday, August 7th. The company reported $0.19 earnings per share for the quarter, missing the consensus estimate of $0.42 by ($0.23). Progyny had a net margin of 4.28% and a return on equity of 10.69%. The firm had revenue of $332.87 million during the quarter, compared to analysts’ expectations of $315.70 million. During the same period in the prior year, the company posted $0.17 EPS. The company’s revenue was up 9.5% compared to the same quarter last year. Progyny has set its Q3 2025 guidance at EPS. FY 2025 guidance at 1.700-1.780 EPS. Analysts predict that Progyny will post 0.6 earnings per share for the current fiscal year.

Insider Buying and Selling

In related news, Director Kevin K. Gordon sold 2,500 shares of Progyny stock in a transaction that occurred on Monday, August 11th. The shares were sold at an average price of $22.04, for a total value of $55,100.00. Following the completion of the sale, the director directly owned 12,501 shares in the company, valued at $275,522.04. This trade represents a 16.67% decrease in their position. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. Also, Director Cheryl Scott sold 2,675 shares of Progyny stock in a transaction that occurred on Wednesday, June 11th. The stock was sold at an average price of $22.07, for a total transaction of $59,037.25. Following the completion of the sale, the director owned 14,112 shares of the company’s stock, valued at $311,451.84. This trade represents a 15.93% decrease in their ownership of the stock. The disclosure for this sale can be found here. 9.40% of the stock is owned by company insiders.

Institutional Trading of Progyny

Institutional investors have recently bought and sold shares of the stock. Cetera Trust Company N.A lifted its stake in Progyny by 303.1% during the 2nd quarter. Cetera Trust Company N.A now owns 1,310 shares of the company’s stock valued at $29,000 after acquiring an additional 985 shares during the period. BI Asset Management Fondsmaeglerselskab A S acquired a new stake in Progyny during the 1st quarter valued at approximately $44,000. Militia Capital Partners LP lifted its stake in Progyny by 100.0% during the 1st quarter. Militia Capital Partners LP now owns 2,000 shares of the company’s stock valued at $45,000 after acquiring an additional 1,000 shares during the period. Brooklyn Investment Group lifted its stake in Progyny by 5,216.4% during the 1st quarter. Brooklyn Investment Group now owns 3,243 shares of the company’s stock valued at $72,000 after acquiring an additional 3,182 shares during the period. Finally, Canada Pension Plan Investment Board acquired a new stake in Progyny during the 2nd quarter valued at approximately $77,000. 94.93% of the stock is currently owned by institutional investors and hedge funds.

Progyny Company Profile

Progyny, Inc, a benefits management company, specializes in fertility and family building benefits solutions in the United States. Its fertility benefits solution includes differentiated benefits plan design, personalized concierge-style member support services, and selective network of fertility specialists.